A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Basal-bolus Therapy in Subjects With Type 2 Diabetes Mellitus
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 506 participants.
Also called NCT02420262
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 506 participants
- Sponsor
- Registry
-
NCT02420262 -
2014-003621-18
-
- Other papers using this trial's data
- Efficacy and Safety of IDegLira Versus Basal-Bolus Insulin Therapy in Patients With Type 2 Diabetes Uncontrolled on Metformin and Basal Insulin: The DUAL VII Randomized Clinical Trial
- The Benefit of Insulin Degludec/Liraglutide (IDegLira) Compared With Basal-Bolus Insulin Therapy is Consistent Across Participant Subgroups With Type 2 Diabetes in the DUAL VII Randomized Trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Argentina, Czechia, France, Greece, Hungary, Israel, Mexico, Russia, Slovakia, Spain, Türkiye
- Registry status
- Completed
Technical summary
Registry record NCT02420262. Randomized; no masking; primary purpose treatment. Start 2015-07-26 (actual); primary completion 2016-10-05 (actual). Results posted on 2017-12-07.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Basal-bolus Therapy in Subjects With Type 2 Diabetes Mellitus
- Condition
- Diabetes
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- insulin degludec/liraglutide
- Intervention (Drug)
- insulin glargine
- Intervention (Drug)
- insulin aspart
- Lead sponsor
- Novo Nordisk A/S
Record details
- Record id
cardio:ct-nct02420262- Content hash
6f12307d1ecc02033d2cbe6186b63afd6df1af188209b9230d7ebd124411f7a1